Advanced Therapy Medicinal Products Market Size, Share and Growth Outlook, 2026

Advanced Therapy Medicinal Products Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Advanced Therapy Medicinal Products Market size is forecast to increase from $43.28 Billion in 2026 to $119.19 Billion in 2034 at a CAGR of 13.5% between 2026 and 2034.

The Advanced Therapy Medicinal Products market report provides detailed analysis and outlook of Advanced Therapy Medicinal Products segments including By Therapy (Gene Therapy Medicines, Cell Therapy Medicines, Tissue-Engineered Products, Combined ATMPs), By Cell Source (Autologous Therapies, Allogeneic Therapies), By Technology Platform (Viral Vector-Based Technologies, Non-Viral Delivery Systems, Gene Editing Technologies), By Indication (Oncology & Hematological Malignancies, Rare Genetic & Inherited Disorders, Cardiovascular Diseases, Neurological & Neurodegenerative Disorders, Musculoskeletal & Orthopedic Disorders, Ophthalmology, Immunological Disorders), By End-User (Hospitals & Certified Surgical Centers, Specialized Clinics & Regenerative Medicine Centers, Academic Medical Centers & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Advanced Therapy Medicinal Products (ATMP) Industry Overview

Gene Therapy Innovation Continues to Drive the ATMP Landscape

The Advanced Therapy Medicinal Products (ATMP) industry is experiencing strong momentum as regulatory agencies increasingly support innovative gene therapies, cell therapies, and regenerative medicine platforms targeting rare and severe diseases. Biotechnology companies are advancing next-generation viral vector technologies, targeted gene insertion systems, and gene regulation approaches designed to address the underlying genetic causes of disease. The sector is characterized by growing utilization of expedited regulatory pathways, including Fast Track, Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Orphan Drug designations, which are helping accelerate clinical development and patient access. Advances in vector engineering, tissue-specific targeting, and durable gene expression are strengthening the potential of ATMPs to deliver long-term therapeutic benefits through single-administration treatments.

Regulatory Designations Accelerate Development of Novel Gene Therapies

Regulatory support remains a major catalyst for innovation across the ATMP market. Complement Therapeutics received FDA Fast Track designation for CTx001, an investigational adeno-associated virus-based gene therapy developed for Geographic Atrophy secondary to age-related macular degeneration. The therapy delivers a truncated Complement Receptor 1, known as mini-CR1, to provide sustained complement pathway regulation and has progressed to patient dosing in a Phase I/II clinical trial. Encoded Therapeutics also secured FDA Breakthrough Therapy designation for ETX101, an AAV9-based gene regulation therapy designed to treat SCN1A-positive Dravet syndrome. Delivered through a single intracerebroventricular administration, the therapy targets inhibitory interneurons to restore endogenous gene expression and builds upon previously granted RMAT and Orphan Drug designations. These developments demonstrate growing confidence in gene therapy platforms designed to address serious neurological and degenerative disorders.

Rare Disease Programs Expand Through Advanced Vector Technologies

The industry is also witnessing significant progress in therapies targeting rare pediatric genetic diseases. Genespire obtained dual Orphan Drug Designation from both the FDA and the European Commission for GENE202, an in vivo gene therapy utilizing an Immune Shielded Lentiviral Vector platform to deliver a functional MMUT gene for the treatment of methylmalonic acidemia. The off-the-shelf approach reflects broader industry efforts to simplify manufacturing and expand patient accessibility. In parallel, iECURE received RMAT designation for ECUR-506, an in vivo targeted gene-insertion therapy utilizing ARCUS nuclease technology for neonatal-onset ornithine transcarbamylase deficiency. The program also secured an Innovation Passport through the United Kingdom’s Innovative Licensing and Access Pathway, facilitating streamlined international clinical development and data collection. These advancements highlight the increasing sophistication of gene-editing, gene-insertion, and vector-based therapeutic technologies that are shaping the future of the global ATMP industry.

Advanced Therapy Medicinal Products Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Advanced Therapy Medicinal Products market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Bristol-Myers Squibb Company, Pfizer Inc., Biogen Inc., Sarepta Therapeutics, Inc., Bluebird Bio, Inc., Spark Therapeutics (Roche), Johnson & Johnson (Janssen), Amgen Inc.. The Advanced Therapy Medicinal Products market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Advanced Therapy Medicinal Products industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Advanced Therapy Medicinal Products Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Advanced Therapy Medicinal Products companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Advanced Therapy Medicinal Products markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Advanced Therapy Medicinal Products Market Competitive Benchmarking and Company Analysis

Leading companies in Advanced Therapy Medicinal Products industry include- Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Bristol-Myers Squibb Company, Pfizer Inc., Biogen Inc., Sarepta Therapeutics, Inc., Bluebird Bio, Inc., Spark Therapeutics (Roche), Johnson & Johnson (Janssen), Amgen Inc.. The Advanced Therapy Medicinal Products market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Advanced Therapy Medicinal Products Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Advanced Therapy Medicinal Products market remains one of the strongest-performing segments in the country.
The US Advanced Therapy Medicinal Products Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Advanced Therapy Medicinal Products market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Advanced Therapy Medicinal Products industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Advanced Therapy Medicinal Products markets

Canada's strong Advanced Therapy Medicinal Products sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Advanced Therapy Medicinal Products market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Advanced Therapy Medicinal Products Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Advanced Therapy Medicinal Products market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Advanced Therapy Medicinal Products population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Advanced Therapy Medicinal Products industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Advanced Therapy Medicinal Products market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Advanced Therapy Medicinal Products sales through 2034

France Advanced Therapy Medicinal Products companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Advanced Therapy Medicinal Products Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Advanced Therapy Medicinal Products distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Advanced Therapy Medicinal Products Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Advanced Therapy Medicinal Products market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Advanced Therapy Medicinal Products industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Advanced Therapy Medicinal Products industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Advanced Therapy Medicinal Products Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Advanced Therapy Medicinal Products market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Advanced Therapy Medicinal Products market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Advanced Therapy Medicinal Products Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Advanced Therapy Medicinal Products Market Segmentation

By Therapy
Gene Therapy Medicines
Cell Therapy Medicines
Tissue-Engineered Products
Combined ATMPs
By Cell Source
Autologous Therapies
Allogeneic Therapies
By Technology Platform
Viral Vector-Based Technologies
Non-Viral Delivery Systems
Gene Editing Technologies
By Indication
Oncology & Hematological Malignancies
Rare Genetic & Inherited Disorders
Cardiovascular Diseases
Neurological & Neurodegenerative Disorders
Musculoskeletal & Orthopedic Disorders
Ophthalmology
Immunological Disorders
By End-User
Hospitals & Certified Surgical Centers
Specialized Clinics & Regenerative Medicine Centers
Academic Medical Centers & Research Institutes

Top Companies in Advanced Therapy Medicinal Products Industry

Novartis AG
Gilead Sciences, Inc. (Kite Pharma)
Bristol-Myers Squibb Company
Pfizer Inc.
Biogen Inc.
Sarepta Therapeutics, Inc.
Bluebird Bio, Inc.
Spark Therapeutics (Roche)
Johnson & Johnson (Janssen)
Amgen Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025